John Moore
About John Moore
John R. Moore is General Counsel at Edgewise Therapeutics and has served in the role since September 2020. He holds a B.S. in chemistry (UNC Chapel Hill), an M.S. in biochemistry (University of Illinois at Urbana-Champaign), and a J.D. (UNC Chapel Hill School of Law) . Company performance context: Edgewise reported negative EBITDA of -$112.8M in FY 2023 and -$156.8M in FY 2024, consistent with a development-stage biopharma profile (no revenues disclosed in these periods) [*]. Moore also serves as Corporate Secretary for annual meetings and acts as inspector of election, anchoring governance process integrity .
| Metric | FY 2023 | FY 2024 |
|---|---|---|
| EBITDA ($USD) | -$112,806,000* | -$156,763,000* |
Values retrieved from S&P Global.*
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| Instil Bio, Inc. | Counsel | Sep–Dec 2020 | Supported legal affairs for a cell therapy developer |
| Peloton Therapeutics, Inc. | General Counsel & Corporate Secretary | Nov 2018–Sep 2019 | Led legal during M&A path toward Merck acquisition, ensuring transactional readiness |
| Consulting engagements | Legal/consulting services | Nov 2018–Sep 2019 | Provided legal support to small companies and non-profits |
| Array BioPharma Inc. | Vice President & General Counsel; Corporate Secretary | 2002–2017 | Oversaw legal function through R&D scale-up and corporate development |
| Wilson Sonsini; Kenyon & Kenyon; Arnold White & Durkee | Attorney | Pre-2002 | IP and corporate law foundation for biopharma legal practice |
External Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| Nivalis Therapeutics, Inc. | Director | Feb 2012–Jul 2017 | Board oversight for a clinical-stage biotech |
Fixed Compensation
| Component | Amount | Effective date | Notes |
|---|---|---|---|
| Base salary | $400,000 | Mar 2021 (IPO effective date) | Increased from $350,000 in confirmatory employment letter |
| Target annual bonus | 40% of base salary | Mar 2021 | Increased from 30% in confirmatory employment letter |
Performance Compensation
Specific performance metric weighting, targets, actuals, and payouts for Moore are not disclosed in proxy tables (he is not listed as a named executive officer). Company-wide incentive frameworks for NEOs focused on Clinical Development, Regulatory, Financing, Business Development/Personnel goals in 2023–2024, with payouts tied to achievement levels; however, these disclosures do not specify Moore’s participation, weights, or payouts . Therefore, detailed metric/payout schedules for Moore are not available in public filings.
Equity Ownership & Alignment
- Eligibility: Moore is eligible for stock options and other equity awards under company plans per his confirmatory employment letter .
- Hedging/pledging: Edgewise prohibits directors and officers from hedging or pledging company stock, and bars transactions in publicly-traded derivatives on company securities, with limited exceptions requiring compliance officer and board-level oversight .
- Insider transactions (recent): Third-party trackers indicate Moore engaged in periodic Form 4 activity, including a small sale on Aug 12, 2025; these are useful for gauging near-term selling pressure but are not comprehensive and should be validated against SEC EDGAR.
| Date | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|
| 2025-08-12 | Sale | 2,098 | $13.3924 | $28,097 | |
| 2025-05-07 | Option exercise | 5,209 | — | — | |
| 2024-09-20 | Sale + Option Exercise (summary) | — | $28.15 | — |
Notes: Aggregators summarize SEC Form 4 filings; use EDGAR for definitive records.
Employment Terms
| Provision | Detail | Source |
|---|---|---|
| Employment status | At-will | Confirmatory employment letter |
| Remote working | Permitted, with travel to Boulder, CO as needed | Confirmatory employment letter |
| Bonus eligibility | Annual cash bonus subject to Board/Comp Committee objectives; target 40% as of IPO | Confirmatory employment letter |
| Equity eligibility | Eligible for stock options and other equity awards under company plans | Confirmatory employment letter |
| Severance | “Severance Agreement” referenced as part of employment terms; specific terms not disclosed in the exhibit excerpt | Confirmatory employment letter |
| Indemnification | Company maintains indemnification agreements with each director and executive officer | 2024 & 2025 proxy |
| Clawback | Compensation Recovery Policy adopted in Oct 2023 consistent with SEC/Nasdaq rules | 2025 proxy |
| Insider trading policy | Robust prohibitions on hedging/pledging; compliance oversight | 2024 & 2025 proxy |
| Meeting governance role | Corporate Secretary; inspector of election for annual meetings | 2024 & 2025 proxy |
Investment Implications
- Compensation alignment and retention: Moore’s structure includes market-standard base+bonus and eligibility for equity, with clawback and anti-hedging/pledging constraints that strengthen shareholder alignment and reduce misaligned risk-taking .
- Insider selling pressure: Recent small sales suggest limited liquidity-taking rather than sustained large-scale selling; monitor ongoing Form 4s for pattern shifts that could signal personal diversification or impending vest/exercise cycles .
- Change-in-control/severance economics: While the Executive Severance Plan is disclosed for NEOs and key employees, Moore’s specific participation terms are not publicly detailed; risk-adjusted retention evaluation should consider existence of a severance agreement but requires direct confirmation for payout multiples or triggers .
- Execution track record: Moore’s prior GC roles at Array BioPharma and Peloton underpin deal-readiness and IP/corporate governance discipline, valuable for a clinical-stage company navigating financings and partnerships .
- Company performance backdrop: Negative EBITDA consistent with pipeline investment phase; governance roles (Corporate Secretary/inspector of election), clawback adoption, and trading policy rigor are positive signals for control environment as the company advances clinical catalysts .
References:
- Executive biography and roles:
- Corporate Secretary/inspector of election role:
- Clawback policy:
- Hedging/pledging prohibitions:
- Indemnification agreements:
- Confirmatory employment letter (comp/terms):
- Insider transaction sources:
- EBITDA (S&P Global): [GetFinancials]